NEWS & ANALYSIS Oncologists hit by sequester budget cuts to the cost of purchasing and administering cancer drugs are hoping that the potentially devastating impact on Medicare cancer patients will force a quick legislative fix in Congress.
PRACTICE & POLICY S. Yousuf Zafar, Amy P. Abernethy;ONCOLOGY Vol. 27 No. 4 Just as high-quality research has focused on limiting the physical toxicity resulting from successful treatment, future research should focus on mitigating the negative effects of financial toxicity without affecting disease-related outcomes.
The US Food and Drug Administration (FDA) has approved asparaginase Erwinia chrysanthemi (Erwinaze) for the treatment of patients with acute lymphoblastic leukemia (ALL), who have developed hypersensitivity to E. coli derived asparaginase and pegaspargase chemotherapy.
The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers.
As insurers, clinicians and the U.S. government attempt to slow the increasing rise of health care costs, many experts have identified the tool entitled “clinical pathways” as a solution. Oncologists who adhere to such pathways are thought to improve patient care and reduce expenses.
The US Food and Drug Administration announced today that it has revoked the approval of bevacizumab for breast cancer due to the potentially life-threatening side effects associated with the treatment. It was approved for metastatic breast cancer in February 2008, but data later showed that along with an increase in side effects, there was no increase in overall survival.
Nationally, the number of drug shortages has tripled since 2005. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited ability to order fluorouracil (5-FU) and mitomycin.
In this review, we discuss the potential applications and limitations of GIS software in oncology research. Our aims are to help clinicians and policy makers interpret studies generated using GIS, and to help clinical investigators implement GIS in future research.
• Examining the Geography of Cancer Incidence and Care
This article summarizes some of the most important federal coverage provisions and safeguards that promote access to preventive services for individuals with cancer or individuals who are at risk for cancer.
A recent epidemiology study by the NCI has found an almost four-fold increase of cancer survivors since 1971: 11.9 million in 2008 compared with 3 million in 1971, and the authors of the study expect a 42% increase in the number of older adult survivors in the next 10 years.
The U.S. Food and Drug Administration (FDA) has approved two new indications for the osteoporosis drug denosumab, as a treatment for bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
A new study of collaborative oncology practice models showed that the greater use of nonphysician practitioners (NPPs) led to an increase in productivity for the practice and was satisfying for both physicians and the NPPs. This provides one potential solution for the predicted shortage of oncologists in the next decade.
QOPI measures are evidenced-based and consensus-based measures that are derived from published research studies, peer-reviewed guidelines, and expert consensus. The mission of QOPI is to provide a means by which oncology practices can continually examine the care they provide, to ensure that each patient receives the best care possible.
The U.S. Food and Drug Administration (FDA) announced last week the approval of brentuximab vedotin, a CD30-directed antibody drug-conjugate, for the treatment of refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
In this interview we discuss the dissemination of research results, clinical trials, and other oncology news using social media, as well as what type of media oncologists use, and how useful and relevant this type of information is for most oncologists.